Colostrum — Research Profile

No. Bovine colostrum contains cow milk proteins (casein, whey) and should be strictly avoided by individuals with dairy/cow milk protein allergy. Those with lactose intolerance may tolerate colostrum (which contains less lactose than regular milk) but should start with a low dose to assess tolerance.

Partially. Bovine IgG has been shown to survive gastric transit to some degree, especially when consumed with food or in large enough quantities. Liposomal delivery and enteric-coated products may improve survival. The growth factors (IGF-1) are more susceptible to acid degradation but some remain bioactive.

Clinical evidence supports this. Playford et al. (2001) showed colostrum prevented the increase in intestinal permeability caused by NSAIDs, and Marchbank et al. (2011) showed similar protection against exercise-induced permeability. The growth factors and immunoglobulins in colostrum support epithelial repair and barrier integrity. Typical dose for gut barrier support is 5-10g daily.

Nearly all human trials used bovine colostrum powder (reconstituted in liquid or delivered in capsules), typically around 20 g/day. Powder versus capsule has not been directly compared, and no form has demonstrated superiority; capsules are convenient but reaching gram-level study doses usually requires powder. The more evidence-relevant variable is preserved immunoglobulin content, not the delivery format.

The best-supported benefits are in physically active adults: a meta-analysis of 5 trials (152 participants) found bovine colostrum cut upper respiratory symptom days by about 44% (rate ratio 0.56) and episodes by about 38% (rate ratio 0.62), and a separate meta-analysis of 10 trials found reduced intestinal permeability (lactulose/rhamnose ratio mean difference -0.24). Effects on immune-cell markers and athletic performance, including IGF-1, were weak or inconclusive. Both meta-analyses flagged low precision and called for larger, better-powered trials.

No standardized dose is established. Trials have ranged from 1 to 60 g/day, with most of the positive respiratory and gut-permeability results coming from 10 to 20 g/day taken for 8 to 12 weeks. One low-dose trial using just 0.5 to 1.0 g/day found a benefit only in a high-stress subgroup (medical students), so smaller doses have not shown broad effects.

Time of day has not been directly compared in bovine colostrum trials. Exercise gut-permeability studies typically had participants dose daily, often in the period before training, while respiratory-symptom trials used once- or twice-daily dosing without specifying a clock time. Daily consistency across the multi-week course, rather than a particular hour, is what the studied protocols share.

Reported side effects are mild and mostly digestive: unpleasant taste, nausea, flatulence, and diarrhea, with occasional skin rash; no serious adverse events were seen in the reviewed trials. Because bovine colostrum is a cow's-milk product containing dairy proteins and lactose, people with a milk allergy or significant lactose intolerance can react to it and should avoid it.

No well-established clinically significant drug interactions have been documented for bovine colostrum, and trials up to 12 weeks reported no serious adverse events. Interaction data are genuinely limited rather than reassuringly complete, so this is an absence of evidence, not proven safety with every drug. Since it is a dairy product, anyone with a cow's-milk allergy should treat it as they would other milk-derived products.

The clearest (though still modest) evidence is in endurance and heavily training adults aiming to reduce upper respiratory symptom days or exercise-induced intestinal permeability. It is not appropriate for anyone with a cow's-milk allergy. Note that much of the neonatal colostrum research concerns oropharyngeal colostrum given to preterm infants, which is a distinct clinical use and does not translate to adult oral supplementation.

Bovine colostrum does not produce an immediately noticeable effect, and the minimum time to a measurable benefit has not been firmly established. Trials reporting reduced intestinal permeability ran daily courses spanning roughly ten days (hospitalized patients) up to twelve weeks (exercising adults), while the reduction in upper respiratory symptom days emerged over about 8 to 12 weeks of continuous use. Expect a multi-week course rather than same-day results, and note the benefits are objective (fewer sick days, lower gut-permeability markers) rather than something you feel.

The longest controlled trials of bovine colostrum ran about 8 to 12 weeks, mostly at up to 20 g/day, and reported no serious adverse events over that window. Safety beyond roughly 12 weeks of continuous use has not been formally established, so open-ended daily use is not backed by trial data. Because it is a whole dairy product, the main practical limits are mild digestive intolerance and cow's-milk allergy rather than cumulative toxicity.

No tolerable upper limit or toxicity threshold has been established for bovine colostrum. Trials have used doses spanning 1 to 60 g/day without serious adverse events, but larger intakes are more likely to cause gastrointestinal complaints such as nausea, flatulence, and diarrhea. It is treated as a food rather than a compound with a defined overdose ceiling.

Bovine colostrum is a dairy-derived protein concentrate, and no clinically significant negative interactions with other supplements have been documented in the trial literature. Stacking studies are essentially absent, so any specific combination benefit is unproven. The realistic caution is additive digestive upset if paired with other agents that commonly cause GI symptoms.

Bovine colostrum's activity comes from several bioactives — immunoglobulins (chiefly IgG), plus lactoferrin and growth factors — so no single number fully captures potency, but a product that discloses its immunoglobulin (IgG) content is easier to compare than one labeled only "colostrum." High heat can lower a powder's immunoglobulin content, so many products use low-heat or flash processing, though whether this changes real-world benefit has not been demonstrated in humans. Because this is an animal-sourced ingredient with no legally standardized potency, choose bovine colostrum from a manufacturer with third-party testing, and note that most positive trials used plain bovine colostrum powder rather than proprietary blends.